
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing sodium valproate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing valproate, as valproic acid, valproate sodium or divalproex sodium, are listed in tablet, capsule, oral solution and injection forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Sodium valproate (valproate sodium) is an antiepileptic medicine given by injection and by mouth; compounded preparations require a prescription and are not FDA-approved.
Sodium valproate, also called valproate sodium, is the sodium salt of valproic acid. In the blood it exists as the valproate ion; valproic acid also dissociates to the valproate ion, and equivalent doses of valproate sodium injection and divalproex sodium give equivalent plasma levels of it. How it controls seizures is not established; one idea is that it raises levels of the calming brain chemical GABA. Valproate sodium injection is FDA-approved as an intravenous alternative when oral valproate products are temporarily not feasible, for complex partial seizures, simple and complex absence seizures, and multiple seizure types that include absence seizures. Valproic acid oral solution also contains the drug as the sodium salt. A prescriber may order sodium valproate compounded in a form or strength not manufactured; a 1989 volunteer study used valproic acid suppositories prepared in a hospital pharmacy. Compounded preparations are not FDA-approved and require a prescription.
The valproate sodium injection label carries a boxed warning for life-threatening adverse reactions: liver damage, including deaths, especially during the first six months of treatment, with higher risk in children under two and people with mitochondrial disorders; fetal risk, including neural tube defects, other major malformations and decreased IQ; and pancreatitis, including fatal cases. It must not be used by people with significant liver disease, urea cycle disorders, or mitochondrial disorders caused by POLG mutations. Carbapenem antibiotics can drop valproate levels and lead to seizures. Valproate raises lamotrigine levels, and serious skin reactions have been reported with the combination. Aspirin, topiramate (high ammonia) and seizure medicines such as phenytoin and carbamazepine also interact. Do not stop it suddenly. Valproate passes into breast milk at low levels; watch a breastfed infant for jaundice and unusual bruising or bleeding. For side effects, talk to your prescriber or pharmacist.
Valproate sodium exists as the valproate ion in blood; its mechanism is not established, with increased brain GABA proposed (label). StatPearls also describes sodium channel blockade, T-type calcium channel inhibition and HDAC inhibition. Equivalent IV and oral doses give equivalent exposure to valproate ion when IV is infused over 60 minutes. Protein binding is concentration dependent, with the free fraction rising from about 10% to 18.5% across the concentration range studied, and is reduced in older adults and in hepatic or renal disease. Metabolism is almost entirely hepatic: 30 to 50% glucuronidation, over 40% mitochondrial beta-oxidation, under 3% excreted unchanged; mean terminal half-life after IV infusion was 16 hours in monotherapy. Phenytoin, carbamazepine and phenobarbital can double clearance; carbapenems may cause subtherapeutic levels. Labeled indications (valproate sodium injection): IV alternative for complex partial, absence and mixed seizure types. Valproate is contraindicated for migraine prophylaxis in pregnancy and in women of childbearing potential not using contraception. StatPearls lists off-label uses, including status epilepticus and bipolar mania; these are not FDA-approved indications for the injection. A 1989 volunteer study measured rectal absorption of valproic acid suppositories. Dosing per prescriber. Monitor liver tests, platelets and coagulation, ammonia, and serum valproate levels.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth